Absolute Minimum: 1.0 mL serum

3 days upon receipt at reference laboratory.

Serum infliximab (IFX) concentration: <1.0 μg/mL
Antibodies to infliximab (ATI) concentration: <3.1 U/mL

A lower cost option for testing is Adalimumab Activity and 

Neutralizing Antibody, LAB8152.



Obtaining pre-authorization to estimate patient out-of-pocket 

liability is strongly recommended.  Once obtained draw sample at 

patient's next available visit.  Please use the reference link below 

for authorization.



Patient's insurance information must be submitted with the sample.



Advantages

•Anser™ IFX can detect low levels of ATI even in the presence 

 of high levels of circulating drug (60μg/mL of IFX in serum)

•Anser™ IFX can be performed at any time during therapy with

 IFX, with no trough level sampling limitation

•High assay sensitivity, specificity, and accuracy

•Use Anser™ IFX to help determine personalized solutions for

 managing loss of response to IFX

Please print, complete, and submit the Pre-Authorization Form and the Prometheus Test Requisition from Prometheus Lab.